JMP Securities initiated coverage of Enovis with an Outperform rating and $62 price target The analyst believes the recent LimaCorporate transaction is now “largely de-risked,” and that the cost savings and sales synergies that are on the way are not reflected in the stock’s current valuation. With the deal’s close at the beginning of the year, Enovis’ fiscal 2024 results have thus far reflected expected integration related headwinds that have tempered the company’s true growth and earnings potential, which should come to fruition in 2025 and beyond, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENOV:
- Enovis target lowered, added to ‘Tactical Outperform’ list at Evercore ISI
- Enovis to unveil Tarsoplasty Percutaneous Lapidus System at AOFAS Meeting
- Enovis expands EMPOWR Revision Knee system to include EMPOWR Cones
- Enovis introduces STAR Ankle, with e+ Polyethylene
- Enovis raises FY24 adjusted EPS view to $2.62-$2.77 from $2.52-$2.67
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue